🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Uterine Neoplasms

The Ohio State University (OSU) SCREEN Community Program NCT06666192NA1 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Cancer Screening, Discussion, Educational Activity, Educational Intervention, Focus Group An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors NCT05366478Phase 11 site📍 Tianjin Suzhou BlueHorse Therapeutics Co., Ltd. · Tests: Autologous tumor infiltrating lymphocytes (TILs) Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health Intra-lesional Tumor Boost for Bulky Cervical Cancer NCT07435376Phase 21 site📍 Seongnam-si Seoul National University Bundang Hospital · Tests: intra-lesional boost IMRT, High Dose Rate Brachytherapy A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies NCT05803018Phase 1, Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1 Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers NCT03564340Phase 1, Phase 254 sites📍 Birmingham📍 Boston📍 Boston Regeneron Pharmaceuticals · Tests: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations NCT05503797Phase 270 sites📍 Beverly Hills📍 San Francisco📍 Westwood, Los Angeles Fore Biotherapeutics · Tests: Plixorafenib 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India NCT07209917NA4 sites📍 Bangalore📍 Bangalore📍 Bangalore University of California, Irvine · Tests: SAKHI HPV Intervention, Enhanced Standard of Care (SOC+) A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting NCT07022483Phase 386 sites📍 Fort Lauderdale📍 Miami📍 Miami Beach Daiichi Sankyo · Tests: Trastuzumab Deruxtecan, Chemotherapy Institut Paoli Calmettes Cervical Cancer Database NCT02869490n/a1 site📍 Marseille Institut Paoli-Calmettes · Tests: Data collection A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) NCT07108270Phase 21 site📍 Jinan GlaxoSmithKline · Tests: Dostarlimab, Carboplatin, Paclitaxel Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT). NCT07022470Phase 21 site📍 Palo Alto Stanford University · Tests: 3-Fraction HDR Brachytherapy, 4-Fraction HDR Brachytherapy a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer NCT06360653NA2 sites📍 Palermo📍 Palermo ARNAS Civico Di Cristina Benfratelli Hospital · Tests: Stereotactic Post-operative Radiotherapy for Endometrial Cancer Single cEll pRofiling PErsistaNce To ImmuNothErapy NCT06680739Phase 21 site📍 Barcelona Vall d'Hebron Institute of Oncology · Tests: Durvalumab, Tremelimumab DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER NCT07690540NA1 site📍 Milan European Institute of Oncology · Tests: Prospective exploratory cohort Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors NCT06974110Phase 115 sites📍 Phoenix📍 San Diego📍 Tampa MOMA Therapeutics · Tests: MOMA-341, Irinotecan, Immunotherapy Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma NCT05603910Phase 11 site📍 Miami Aaron Wolfson · Tests: Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy, High-Dose Rate (HDR) Brachytherapy Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy NCT06024109n/a2 sites📍 Frankfurt am Main📍 Manresa Aesculap AG · Tests: Closure of the Vaginal Cuff after Total Hysterectomy Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC NCT03463252Phase 2, Phase 31 site📍 Chengdu West China Second University Hospital · Tests: Progesterone, Mirena®, GnRH agonist Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer NCT05735145Phase 31 site📍 Liuzhou Fourth Affiliated Hospital of Guangxi Medical University · Tests: paclitaxel combined with platinum A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer NCT07054567Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Pembrolizumab, Bevacizumab European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Lymphadenectomy Followed by Therapeutic Pelvic and Paraaortic Lymphadenectomy in Node Positive Disease for Locoregional Control in Endometrial Cancer FIGO Stages I-III NCT04504006n/a1 site📍 Essen Dr. Paul Buderath · Tests: Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL) Community, Home-based Education, Screening Services Strategy to Increase Cervical Cancer Control Access for HIV-Positive Women in Nigeria NCT06751030n/a3 sites📍 Abuja📍 Ibadan📍 Lagos Emory University · Tests: The Mother Mentor program, GeneXpert HPV test A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer NCT07080216Phase 1, Phase 21 site📍 Hangzhou Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZG005, Gecacitinib, Bevacizumab A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors NCT07814248Phase 13 sites📍 Maumee📍 Portland📍 Fairfax TwoStep Therapeutics, Inc. · Tests: TS-104 Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer NCT06140589n/a1 site📍 Fuzhou Fujian Cancer Hospital · Tests: Cadonilimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy